APTO News and Press, Aptose Biosciences Inc. From 12/12/22

Aptose Biosciences ( NASDAQ: APTO ) said on Monday it had entered into an equity distribution agreement of up to $50M with JonesTrading Institutional Services as agent. Under the terms of the equity distribution agreement, the company can issue and sell through the agent, common s...

Company Provides Comprehensive Clinical Update from Phase 1/2 Trial Tuspetinib Continues to Deliver Single Agent Responses in r/r AML Patients Tuspetinib Safety and Efficacy Profile may Position Drug to Become the Preferred Kinase Inhibitor for Triplet Combination, Mainten...

SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan...

SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patie...

Summary Aptose is moving tuspetinib into expansion studies as a single-agent drug in mutation-dominant AML subtypes and in combination with Venclexta in relapsed/refractory AML. Cross-trial comparisons are always problematic, but initial reads on the efficacy of tuspetinib in hard...

Aptose Biosciences ( NASDAQ: APTO ) jumped ~26% after the Canadian biotech announced that abstracts containing clinical data for its leukemia candidates tuspetinib (formerly HM43239) and luxeptinib (CG-806) were available at the ASH conference website. Data from these ...

SAN DIEGO and TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for tu...

Aptose Biosciences Inc. (APTO) Q3 2022 Results Conference Call November 01, 2022 05:00 PM ET Company Participants Susan Pietropaolo - Managing Director William Rice - Chairman, President and CEO Fletcher Payne - SVP and Chief Financial Officer Rafael Bejar - ...

Aptose Biosciences ( NASDAQ: APTO ): Q3 GAAP EPS of -$0.11 beats by $0.01 . Total cash and cash equivalents and investments as of September 30, 2022 were $55.4 million. For further details see: Aptose Biosciences GAAP EPS of -$0.11 beats by $0.01

─ Tuspetinib (HM43239) Dose Escalation and Exploration Phase 1/2 Trial in r/r AML Complete; Continued Superior Safety Profile and Clinical Responses Including Complete Remissions as Single Agent Across Three Dose Levels ─ ─ Recruitment Open for Tuspetinib Dose...